title: Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
abstract: OBJECTIVE
  PRRT is a known tool in the management of patients with disseminated and inoperable NETs. The aim of study was to assess the effectiveness of the repeated cycles of PRRT in patients with disseminated and inoperable NETs.
  
  
  METHODS
  Eighty nine patients were included in the PRRT. Among them 16 patients (18%) were qualified for a repeated PRRT cycle due to progression of the disease. In one of the patients qualified for the repeated cycle, PRRT was used as neoadjuvant therapy. The results and side-effects of the repeated cycles of PRRT were analyzed.
  
  
  RESULTS
  Disease stabilization was observed in 10 patients 6 months after the repeated PRRT cycle and in 5 patients after 12 and 18 months. Ten of the patients who had received repeated PRRT cycles died. In the case of neoadjuvant therapy, further reduction of the tumor size was observed, enabling qualification for surgery. Clinically significant reduction in the mean values of morphological parameters was not observed. Only after 12 and 18 months the mean values of creatinine levels were higher than the normal range (only in 2 patients).
  
  
  CONCLUSIONS
  The repeated cycles of PRRT did not cause a clinically significant increase of the toxicity of PRRT. The changes in kidney and blood morphology parameters were transient. The repeated cycles of PRRT enabled stabilization of the disease.
authors: Nuclear Medicine Unit, Endocrinology Department, Jagiellonian University, Krakow, Poland. pachdor@cm-uj.krakow.pl
authors: Dorota
authors: D
authors: Pach
authors: Anna
authors: A
authors: Sowa-Staszczak
authors: Jolanta
authors: J
authors: Kunikowska
authors: Leszek
authors: L
authors: Królicki
authors: Małgorzata
authors: M
authors: Trofimiuk
authors: Agnieszka
authors: A
authors: Stefańska
authors: Monika
authors: M
authors: Tomaszuk
authors: Bogusław
authors: B
authors: Głowa
authors: Renata
authors: R
authors: Mikołajczak
authors: Dariusz
authors: D
authors: Pawlak
authors: Agata
authors: A
authors: Jabrocka-Hybel
authors: Alicja B
authors: AB
authors: Hubalewska-Dydejczyk
mesh_terms: D000368:Aged; D003952:Diagnostic Imaging; D018450:Disease Progression; D005260:Female; D006801:Humans; D008187:Lutetium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D018358:Neuroendocrine Tumors / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use*; D011868:Radioisotopes / Q000627:therapeutic use*; D018000:Receptors, Peptide / Q000627:therapeutic use*; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D047368:Tumor Burden / Q000528:radiation effects; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: C539274:90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)-; D009942:Organometallic Compounds; D011868:Radioisotopes; D018000:Receptors, Peptide; D015021:Yttrium Radioisotopes; D008187:Lutetium; D015282:Octreotide